Pacira | PCRX - Cost Of Sales

Stock Price
21.91
Daily Change
-0.68 -3.01%
Monthly
7.51%
Yearly
-8.90%
Q1 Forecast
22.50

Pacira reported $54.62M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Assertio Holdings USD 8.89M 2.29M Jun/2024
Astellas Pharma JPY 149.13B 10.88B Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Coherus Biosciences USD 2.65M 31.2M Mar/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
J&J USD 7.97B 689M Dec/2025
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novo Nordisk DKK 15.15B 2.3B Dec/2025
Omeros USD 33.16M 18.52M Jun/2024
Pacira USD 54.62M 6.02M Dec/2025
Perrigo USD 747.4M 81.2M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Supernus Pharmaceuticals USD 47.53M 4.24M Dec/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025
Xeris Pharmaceuticals USD 13.71M 1.81M Sep/2025
Xoma 116K 112.7K Jun/2024
Zoetis USD 743M 60M Dec/2025